370 related articles for article (PubMed ID: 22038994)
1. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.
Landreville S; Agapova OA; Matatall KA; Kneass ZT; Onken MD; Lee RS; Bowcock AM; Harbour JW
Clin Cancer Res; 2012 Jan; 18(2):408-16. PubMed ID: 22038994
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo anti-uveal melanoma activity of JSL-1, a novel HDAC inhibitor.
Wang Y; Liu M; Jin Y; Jiang S; Pan J
Cancer Lett; 2017 Aug; 400():47-60. PubMed ID: 28455241
[TBL] [Abstract][Full Text] [Related]
3. Verification of EZH2 as a druggable target in metastatic uveal melanoma.
Jin B; Zhang P; Zou H; Ye H; Wang Y; Zhang J; Yang H; Pan J
Mol Cancer; 2020 Mar; 19(1):52. PubMed ID: 32127003
[TBL] [Abstract][Full Text] [Related]
4. The Role of Histone Deacetylase Inhibitors in Uveal Melanoma: Current Evidence.
Moschos MM; Dettoraki M; Androudi S; Kalogeropoulos D; Lavaris A; Garmpis N; Damaskos C; Garmpi A; Tsatsos M
Anticancer Res; 2018 Jul; 38(7):3817-3824. PubMed ID: 29970501
[TBL] [Abstract][Full Text] [Related]
5. BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma.
Matatall KA; Agapova OA; Onken MD; Worley LA; Bowcock AM; Harbour JW
BMC Cancer; 2013 Aug; 13():371. PubMed ID: 23915344
[TBL] [Abstract][Full Text] [Related]
6. Dual Screen for Efficacy and Toxicity Identifies HDAC Inhibitor with Distinctive Activity Spectrum for BAP1-Mutant Uveal Melanoma.
Kuznetsoff JN; Owens DA; Lopez A; Rodriguez DA; Chee NT; Kurtenbach S; Bilbao D; Roberts ER; Volmar CH; Wahlestedt C; Brothers SP; Harbour JW
Mol Cancer Res; 2021 Feb; 19(2):215-222. PubMed ID: 33077485
[TBL] [Abstract][Full Text] [Related]
7. Targeting primary and metastatic uveal melanoma with a G protein inhibitor.
Onken MD; Makepeace CM; Kaltenbronn KM; Choi J; Hernandez-Aya L; Weilbaecher KN; Piggott KD; Rao PK; Yuede CM; Dixon AJ; Osei-Owusu P; Cooper JA; Blumer KJ
J Biol Chem; 2021; 296():100403. PubMed ID: 33577798
[TBL] [Abstract][Full Text] [Related]
8. BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors.
Han A; Purwin TJ; Bechtel N; Liao C; Chua V; Seifert E; Sato T; Schug ZT; Speicher DW; Harbour JW; Aplin AE
Oncogene; 2021 Jan; 40(3):618-632. PubMed ID: 33208912
[TBL] [Abstract][Full Text] [Related]
9. Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3.
Lai F; Guo ST; Jin L; Jiang CC; Wang CY; Croft A; Chi MN; Tseng HY; Farrelly M; Atmadibrata B; Norman J; Liu T; Hersey P; Zhang XD
Cell Death Dis; 2013 Jun; 4(6):e655. PubMed ID: 23744355
[TBL] [Abstract][Full Text] [Related]
10. Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer.
Wilson PM; Labonte MJ; Martin SC; Kuwahara ST; El-Khoueiry A; Lenz HJ; Ladner RD
Invest New Drugs; 2013 Aug; 31(4):845-57. PubMed ID: 23299388
[TBL] [Abstract][Full Text] [Related]
11. Transposase mapping identifies the genomic targets of BAP1 in uveal melanoma.
Yen M; Qi Z; Chen X; Cooper JA; Mitra RD; Onken MD
BMC Med Genomics; 2018 Nov; 11(1):97. PubMed ID: 30400891
[TBL] [Abstract][Full Text] [Related]
12. The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity.
Woods DM; Woan K; Cheng F; Wang H; Perez-Villarroel P; Lee C; Lienlaf M; Atadja P; Seto E; Weber J; Sotomayor EM; Villagra A
Melanoma Res; 2013 Oct; 23(5):341-8. PubMed ID: 23963286
[TBL] [Abstract][Full Text] [Related]
13. Depsipeptide (FR901228) inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines.
Klisovic DD; Katz SE; Effron D; Klisovic MI; Wickham J; Parthun MR; Guimond M; Marcucci G
Invest Ophthalmol Vis Sci; 2003 Jun; 44(6):2390-8. PubMed ID: 12766035
[TBL] [Abstract][Full Text] [Related]
14. Targeting of histone deacetylases to reactivate tumour suppressor genes and its therapeutic potential in a human cervical cancer xenograft model.
Feng D; Wu J; Tian Y; Zhou H; Zhou Y; Hu W; Zhao W; Wei H; Ling B; Ma C
PLoS One; 2013; 8(11):e80657. PubMed ID: 24260446
[TBL] [Abstract][Full Text] [Related]
15. Natural withanolide withaferin A induces apoptosis in uveal melanoma cells by suppression of Akt and c-MET activation.
Samadi AK; Cohen SM; Mukerji R; Chaguturu V; Zhang X; Timmermann BN; Cohen MS; Person EA
Tumour Biol; 2012 Aug; 33(4):1179-89. PubMed ID: 22477711
[TBL] [Abstract][Full Text] [Related]
16. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
Garrett LA; Growdon WB; Rueda BR; Foster R
J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
[TBL] [Abstract][Full Text] [Related]
17. HDAC Inhibition Enhances the
Faião-Flores F; Emmons MF; Durante MA; Kinose F; Saha B; Fang B; Koomen JM; Chellappan SP; Maria-Engler SS; Rix U; Licht JD; Harbour JW; Smalley KSM
Clin Cancer Res; 2019 Sep; 25(18):5686-5701. PubMed ID: 31227503
[TBL] [Abstract][Full Text] [Related]
18. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance.
Shao W; Growney JD; Feng Y; O'Connor G; Pu M; Zhu W; Yao YM; Kwon P; Fawell S; Atadja P
Int J Cancer; 2010 Nov; 127(9):2199-208. PubMed ID: 20127862
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors repress chondrosarcoma cell proliferation.
Zhu J; Gu J; Ma J; Xu Z; Tao H
J BUON; 2015; 20(1):269-74. PubMed ID: 25778327
[TBL] [Abstract][Full Text] [Related]
20. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]